相关实验视频
Updated: Jul 14, 2026
07:23
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
7.1K
索尼克罗曼醇通过线粒体和热死调节缓解败血症引起的心脏损伤
Xinxin Qi1, Liang Zhao2, Yan Zou3
1Department of Critical Care, Wuhan University of Science and Technology Affiliated Puren Hospital, Hubei, Wuhan, China.
Journal of physiological investigation
|September 17, 2025
概括
索尼克罗曼醇通过改善线粒体功能,减少炎症和热死来防止败血症引起的心肌功能障碍. 这种药物显示出作为治疗败血症相关心脏损伤的新疗法的潜力.
科学领域:
- 心血管研究研究心血管研究
- 线粒体生物学 线粒体生物学
- 败血症病理生理学
背景情况:
- 败血症诱导的心肌功能障碍 (SIMD) 是一种危及生命的疾病,与线粒体功能障碍,炎症和热有关.
- 作为氧化还原调节剂的sonlicromanol可以保持线粒体功能,但其在SIMD中的有效性尚未得到证实.
研究的目的:
- 评估sonlicromanol对心脏功能和心肌损伤的保护作用,在毒症的老鼠模型中.
- 调查sonlicromanol对SIMD中线粒体动力学,线粒体和炎症酶-炎症酶解毒路径的影响.
主要方法:
- 在老鼠中,通过结和穿孔 (CLP) 诱导了败血症.
- 索尼克罗曼醇在CLP前两周服用,一些组接受Mdivi-1 (线粒细胞衰减抑制剂).
- 用各种生化和组织学技术评估了心脏功能,心肌损伤,热致死,线粒体和线粒体动力学.
主要成果:
- 患有CLP的老鼠表现出心脏功能受损,损伤标志物升高,质亡增加,并减少了线粒体和线粒体功能.
- 索尼克罗曼醇治疗显著改善了心脏功能,减少了心肌损伤,抑制了热致死,恢复了线粒体动力学,增强了线粒体和改善了线粒体功能.
- 与Mdivi-1的同时使用部分逆转了sonlicromanol的有益作用,突出了线粒体动力学和线粒细胞衰变的作用.
结论:
- 索尼克罗曼醇通过调节线粒体平衡和抑制热致死,有效地改善了败血症引起的心肌功能障碍.
- 索尼克罗曼醇是一种有前途的治疗候选药物,用于治疗与败血症相关的心脏并发症.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:28Cardiac Catheterization I: Pre-Procedure Overview
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...